1.Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma
Hyerim HA ; Bhumsuk KEAM ; Chan-Young OCK ; Tae Min KIM ; Jin Ho KIM ; Eun-Jae CHUNG ; Seong Keun KWON ; Soon-Hyun AHN ; Hong-Gyun WU ; Myung-Whun SUNG ; Dae Seog HEO
The Korean Journal of Internal Medicine 2021;36(1):175-181
Background/Aims:
Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor characterized by indolence, with a high rate of local recurrence and distant metastasis. This study aimed to investigate the effect of concurrent chemoradiation (CCRT) on locally advanced unresectable ACC.
Methods:
We retrospectively analyzed clinical data from 10 patients with pathologically confirmed ACC of the head and neck who received CCRT with cisplatin in Seoul National University Hospital between 2013 and 2018.
Results:
Ten patients with unresectable disease at the time of diagnosis or with positive margins after surgical resection received CCRT with weekly cisplatin. Eight patients (80%) achieved complete remission, of which three later developed distant metastases without local relapse; one patient developed distant metastasis and local relapse. Two patient achieved partial remission without progression. Patients experienced several toxicities, including dry mouth, radiation dermatitis, nausea, and salivary gland inflammation of mostly grade 1 to 2. Only one patient showed grade 3 oral mucositis. Median relapse-free survival was 34.5 months (95% confidence interval, 22.8 months to not reached).
Conclusions
CCRT with cisplatin is effective for local control of ACC with manageable toxicity and may be an effective treatment option for locally advanced unresectable ACC.
2.Failure patterns of cervical lymph nodes in metastases of unknown origin according to target volume
Dong-Yun KIM ; Dae Seog HEO ; Bhumsuk KEAM ; Chan Young OCK ; Soon Hyun AHN ; Ji-hoon KIM ; Kyeong Cheon JUNG ; Jin Ho KIM ; Hong-Gyun WU
Radiation Oncology Journal 2020;38(1):18-25
Purpose:
This study was aim to evaluate the patterns of failure according to radiotherapy (RT) target volume for cervical lymph nodes in metastases of unknown primary origin in head and neck region (HNMUO).
Materials and Methods:
Sixty-two patients with HNMUO between 1998 and 2016 were retrospectively reviewed. We analyzed the clinical outcomes and primary site failure depending on the radiation target volume. The target volume was classified according to whether the potential head and neck mucosal sites were included and whether the neck node was treated involved side only or bilaterally.
Results:
Potential mucosal site RT (mucosal RT) was done to 23 patients and 39 patients did not receive mucosal RT. Mucosal RT showed no significant effect on overall survival (OS) and locoregional recurrence (LRR). The location of primary site failure encountered during follow-up period was found to be unpredictable and 75% of patients with recurrence received successful salvage therapies. No significant differences in OS and LRR were found between patients treated to unilateral (n = 35) and bilateral neck irradiation (n = 21). Treatment of both necks resulted in significantly higher mucositis.
Conclusions
We found no advantages in OS and LRR of patients with HNMUO when mucosal sites and bilateral neck node were included in the radiation target volume.
3.Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma
Hansang LEE ; Dongryul OH ; Kyungmi YANG ; Young Hyeh KO ; Yong Chan AHN ; Won Seog KIM ; Seok Jin KIM
Cancer Research and Treatment 2019;51(2):547-555
PURPOSE: Duodenal-type follicular lymphoma (FL) is a rare variant of FL. There is still no consensus on the initial treatment, and clinical features including endoscopic findings are not familiar to most physicians. The objective of this study was to evaluate the outcome of patients who were initially treated with radiation therapy for duodenal-type FL. MATERIALS AND METHODS: We retrospectively analyzed 20 patients who were consecutively diagnosed with duodenal-type FL between 2008 and 2017. All patients received radiation therapywith curative intent. RESULTS: The median age of the patients was 52 years (range, 26 to 66 years), and females were predominant. Most patients (n=18, 90%) had stage I disease, and were diagnosed by a regular health examination in an asymptomatic state. The histological grade was one in 19 patients (95%), and the endoscopic findings were diffuse nodular (n=8), whitish granular (n=8), and mixed pattern (n=4). Radiation therapy was delivered to 17 patients with 24 Gy in 12 fractions, and to three patients with 30.6-36 Gy in 18 fractions. All patients were evaluated with endoscopy for response to radiation therapy, and complete response was achieved in 19 patients (95%). At the time of analysis, all patients survived without any evidence of late toxicities related with radiation therapy. CONCLUSION: Taken together, radiation therapy alone could be effective in controlling duodenal lesion. A further study with longer follow-up duration is warranted to confirm our findings.
Asymptomatic Diseases
;
Consensus
;
Duodenum
;
Endoscopy
;
Female
;
Follow-Up Studies
;
Humans
;
Lymphoma, Follicular
;
Retrospective Studies
4.Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma.
Ga In LEE ; Dongryul OH ; Won Seog KIM ; Seok Jin KIM ; Young Hyeh KO ; Kyung In WOO ; Yoon Duck KIM ; Yong Chan AHN
Cancer Research and Treatment 2018;50(2):575-581
PURPOSE: The purpose of this study was to evaluate the clinical features and the long-term outcomes of primary conjunctival marginal zone B-cell lymphoma (MZBCL) patients who were treated with radiation therapy (RT). MATERIALS AND METHODS: Retrospective data of 79 patients with 121 primary conjunctival MZBCL lesions were collected from January 1, 2001 till June 30, 2014. All lesions were treated by local RT (26 Gy) with patient-specific customized lens-shielding device. RESULTS: The current Korean patients' cohort showed younger median age at diagnosis (38 years), great female preponderance (78.5%) and more frequent bilateral involvement (53.2%) than the previous studies. Following 26 Gy's RT, excellent clinical outcomes were achieved: 5-year rates of overall survival, local relapse-free survival, and contralateral relapse-free survival were 100%, 98.1%, and 91.5%, respectively. Two patients (2.5%) developed local relapse and five (6.3%) developed relapse at initially uninvolved contralateral conjunctiva with median interval of 52.9 months, and late adverse events of grade 2 and 3 occurred in seven (8.8%) and two (2.5%) patients, respectively. CONCLUSION: 26 Gy's RT was highly effective and safe, with the use of lens-shielding device, in treating patients with primary conjunctival MZBCL.
Cohort Studies
;
Conjunctiva
;
Diagnosis
;
Female
;
Humans
;
Lymphoma, B-Cell, Marginal Zone*
;
Radiotherapy
;
Recurrence
;
Retrospective Studies
5.ERRATUM: Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy.
Min Kyu KANG ; Dongryul OH ; Kwan Ho CHO ; Sung Ho MOON ; Hong Gyun WU ; Dae Seog HEO ; Yong Chan AHN ; Keunchil PARK ; Hyo Jung PARK ; Jun Su PARK ; Ki Chang KEUM ; Jihye CHA ; Jun Won KIM ; Yeon Sil KIM ; Jin Hyoung KANG ; Young Taek OH ; Ji Yoon KIM ; Sung Hwan KIM ; Jin Hee KIM ; Chang Geol LEE
Cancer Research and Treatment 2016;48(1):425-425
In this article, an protocol number error was found in the last paragraph of the introduction part, page 872.
6.Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy.
Min Kyu KANG ; Dongryul OH ; Kwan Ho CHO ; Sung Ho MOON ; Hong Gyun WU ; Dae Seog HEO ; Yong Chan AHN ; Keunchil PARK ; Hyo Jung PARK ; Jun Su PARK ; Ki Chang KEUM ; Jihye CHA ; Jun Won KIM ; Yeon Sil KIM ; Jin Hyoung KANG ; Young Taek OH ; Ji Yoon KIM ; Sung Hwan KIM ; Jin Hee KIM ; Chang Geol LEE
Cancer Research and Treatment 2015;47(4):871-878
PURPOSE: To define the role of neoadjuvant and concurrent chemotherapy in stage II nasopharyngeal carcinoma, we compared the treatment outcomes of patients treated with curative radiotherapy with or without chemotherapy. MATERIALS AND METHODS: From 2004 to 2011, 138 patients with American Joint Committee on Cancer (AJCC) 2002 stage II nasopharyngeal carcinoma were treated with curative radiotherapy in 12 hospitals in South Korea. Treatment methods included radiotherapy alone in 34 patients, neoadjuvant chemotherapy followed by radiotherapy alone in seven, concurrent chemoradiotherapy in 80, and neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in 17. Adjuvant chemotherapy was used in 42 patients. Total radiation dose ranged from 64 Gy to 74.2 Gy (median, 70 Gy). RESULTS: Median follow-up was 48 months (range, 7 to 97 months) for all patients. At the last follow-up, 13 patients had died and 32 had experienced treatment failure; locoregional failure occurred in 14, distant failure in 16, and both in two. Five-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival were 86.2%, 85.5%, 74.4%, and 88.2%, respectively. Multivariate analyses showed that the significant prognostic factors were concurrent chemotherapy and N stage for locoregional relapse-free survival, concurrent chemotherapy for progression-free survival, and age and N stage for overall survival. Neither neoadjuvant nor concurrent chemotherapy improved distant metastasis-free survival. CONCLUSION: Concurrent chemotherapy significantly improved 5-year locoregional relapse-free survival and progression-free survival in stage II nasopharyngeal carcinoma. However, neoadjuvant chemotherapy failed to improve either.
Chemoradiotherapy
;
Chemotherapy, Adjuvant
;
Disease-Free Survival
;
Drug Therapy*
;
Follow-Up Studies
;
Humans
;
Joints
;
Korea
;
Multivariate Analysis
;
Radiotherapy*
;
Treatment Failure
7.Current Status of Laparoscopic Liver Resection in Korea.
Joon Seong PARK ; Ho Seong HAN ; Dae Wook HWANG ; Yoo Seok YOON ; Jai Young CHO ; Yang Seok KOH ; Choon Hyuck David KWON ; Kyung Sik KIM ; Sang Bum KIM ; Young Hoon KIM ; Hyung Chul KIM ; Chong Woo CHU ; Dong Shik LEE ; Hong Jin KIM ; Sang Jae PARK ; Sung Sik HAN ; Tae Jin SONG ; Young Joon AHN ; Yung Kyung YOO ; Hee Chul YU ; Dong Sup YOON ; Min Koo LEE ; Hyeon Kook LEE ; Seog Ki MIN ; Chi Young JEONG ; Soon Chan HONG ; In Seok CHOI ; Kyung Yul HUR
Journal of Korean Medical Science 2012;27(7):767-771
Since laparoscopic liver resection was first introduced in 2001, Korean surgeons have chosen a laparoscopic procedure as one of the treatment options for benign or malignant liver disease. We distributed and analyzed a nationwide questionnaire to members of the Korean Laparoscopic Liver Surgery Study Group (KLLSG) in order to evaluate the current status of laparoscopic liver resection in Korea. Questionnaires were sent to 24 centers of KLLSG. The questionnaire consisted of operative procedure, histological diagnosis of liver lesions, indications for resection, causes of conversion to open surgery, and postoperative outcomes. A laparoscopic liver resection was performed in 416 patients from 2001 to 2008. Of 416 patients, 59.6% had malignant tumors, and 40.4% had benign diseases. A total laparoscopic approach was performed in 88.7%. Anatomical laparoscopic liver resection was more commonly performed than non-anatomical resection (59.9% vs 40.1%). The anatomical laparoscopic liver resection procedures consisted of a left lateral sectionectomy (29.3%), left hemihepatectomy (19.2%), right hemihepatectomy (6%), right posterior sectionectomy (4.3%), central bisectionectomy (0.5%), and caudate lobectomy (0.5%). Laparoscopy-related serious complications occurred in 12 (2.8%) patients. The present study findings provide data in terms of indication, type and method of liver resection, and current status of laparoscopic liver resection in Korea.
*Hepatectomy/statistics & numerical data
;
Humans
;
*Laparoscopy/statistics & numerical data
;
Liver/*surgery
;
Liver Diseases/pathology/surgery
;
Liver Neoplasms/pathology/surgery
;
Postoperative Complications/epidemiology
;
Questionnaires
;
Republic of Korea
8.Prognostic Value of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (bFGF) Expression in Resected Non-small Cell Lung Cancer.
Seung Joon KIM ; Jung Mi LEE ; Jin Sook KIM ; Ji Young KANG ; Sang Hak LEE ; Seok Chan KIM ; Sook Young LEE ; Chi Hong KIM ; Joong Hyun AHN ; Soon Seog KWON ; Young Kyoon KIM ; Kwan Hyoung KIM ; Hwa Sik MOON ; Jeong Sup SONG ; Sung Hak PARK ; Seok Hwan MOON ; Yeong Pil WANG
Tuberculosis and Respiratory Diseases 2008;64(3):200-205
BACKGROUND: Tumor angiogenesis plays an important role in tumor growth, maintenance and metastatic potential. Tumor tissue produces many types of angiogenic growth factors. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have both been implicated to have roles in tumor angiogenesis. In this study, the expression of tissue VEGF and bFGF from non-small cell lung cancer (NSCLC) patients were analyzed. METHODS: We retrospectively investigated 35 patients with a histologically confirmed adenocarcinoma or squamous cell carcinoma of the lung, where the primary curative approach was surgery. An ELISA was employed to determine the expression of VEGF and bFGF in extracts prepared from 35 frozen tissue samples taken from the cancer patients. RESULTS: VEGF and bFGF concentrations were significantly increased in lung cancer tissue as compared with control (non-cancerous) tissue. The VEGF concentration was significantly increased in T2 and T3 cancers as compared with T1 cancer. Expression of VEGF was increased in node-positive lung cancer tissue as compared with node-negative lung cancer tissue (p=0.06). VEGF and bFGF expression were not directly related to the stage of lung cancer and patient survival. CONCLUSION: Expression of VEGF and bFGF were increased in lung cancer tissue, and the expression of VEGF concentration in lung cancer tissue was more likely related with tumor size and the presence of a lymph node metastasis than the expression of bFGF. However, in this study, expression of both VEGF and bFGF in tissue were not associated with patient prognosis.
Adenocarcinoma
;
Carcinoma, Non-Small-Cell Lung
;
Carcinoma, Squamous Cell
;
Enzyme-Linked Immunosorbent Assay
;
Fibroblast Growth Factor 2
;
Humans
;
Intercellular Signaling Peptides and Proteins
;
Lung
;
Lung Neoplasms
;
Lymph Nodes
;
Neoplasm Metastasis
;
Prognosis
;
Retrospective Studies
;
Vascular Endothelial Growth Factor A
9.Time Sequence of Airway Remodeling in a Mouse Model of Chronic Asthma: the Relation with Airway Hyperresponsiveness.
Seung Joon KIM ; Chi Hong KIM ; Joong Hyun AHN ; Myung Sook KIM ; Seok Chan KIM ; Sook Young LEE ; Soon Seog KWON ; Young Kyoon KIM ; Kwan Hyoung KIM ; Hwa Sik MOON ; Jeong Sup SONG ; Sung Hak PARK
Journal of Korean Medical Science 2007;22(2):183-191
During the course of establishing an animal model of chronic asthma, we tried to elucidate the time sequence of airway hyperresponsiveness (AHR), airway inflammation, airway remodeling, and associated cytokines. Seven-week-old female BALB/c mice were studied as a chronic asthma model using ovalbumin (OVA). After sensitization, mice were exposed twice weekly to aerosolized OVA, and were divided into three groups depending on the duration of 4 weeks, 8 weeks, and 12 weeks. At each time point, airway responsiveness, inflammatory cells, cytokines in bronchoalveolar lavage fluids (BALF), serum OVA-specific IgE, IgG1, IgG2a, and histological examination were carried out. AHR to methacholine, increased levels of OVA-specific IgG1 and IgG2a, and goblet cell hyperplasia were continuously sustained at each time point of weeks. In contrast, we observed a time-dependent decrease in serum OVA-specific IgE, BALF eosinophils, BALF cytokines such as IL-13, transforming growth factor-beta1, and a time-dependent increase in BALF promatrix metalloproteinase-9 and peribronchial fibrosis. In this OVA-induced chronic asthma model, we observed airway remodelings as well as various cytokines and inflammatory cells being involved in different time-dependent manners. However, increased airway fibrosis did not directly correlate with a further increase in airway hyperresponsiveness.
Time Factors
;
Pneumonia/chemically induced/*immunology
;
Ovalbumin
;
Mice, Inbred BALB C
;
Mice
;
Lung/drug effects/*immunology
;
Female
;
*Disease Models, Animal
;
Cytokines/*immunology
;
Chronic Disease
;
Asthma/chemically induced/*immunology
;
Animals
10.Effectiveness of Fentanyl Transdermal Patch (Fentanyl-TTS, Durogegic(R)) for Radiotherapy Induced Pain and Cancer Pain: Multi-center Trial.
Seong Soo SHIN ; Seung Jae HUH ; Eun Kyung CHOI ; Jong Hoon KIM ; Seung Do AHN ; Sang Wook LEE ; Yeun Sil KIM ; Kyu Chan LEE ; Chang Geol LEE ; John JK LOH ; Mison CHUN ; Young Teak OH ; Ok Bae KIM ; Jin Hee KIM ; Chul Yong KIM ; Dae Sik YANG ; Woo Yoon PARK ; Bo Kyoung KIM ; Heung Lae CHO ; Ki Jung AHN ; Jong Young LEE ; Seon Min YUN ; Yong Chan AHN ; Do Hoon LIM ; Won PARK ; Ki Moon KANG ; Hong Gyun WU ; Hyun Soo SHIN ; Seong Soon JANG ; Eun Seog KIM ; Byung Sik NA ; Woong Ki JUNG ; Sung Ja AHN ; Taek Keun NAM ; Yong Ho KIM ; MI Hee SONG ; Sang Mo YUN ; Chul Seung KAY ; Ji Won YEI ; Suk Won PARK ; Seon Woo KIM
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2006;24(4):263-271
PURPOSE: To evaluate the effectiveness and safety of fentanyl-TTS in the management of radiotherapy induced acute pain and cancer pain treated with radiotherapy. MATERIALS AND METHODS: Our study was open labelled prospective phase IV multi-center study. the study population included patients with more 4 numeric rating scale(NRS) score pain although managed with other analgesics or more than 6 NRS score pain without analgesics. Patients divided into two groups; patients with radiotherapy induced pain (Group A) and patients with cancer pain treated with radiotherapy (Group B). All patients received 25 ug/hr of fentanyl transdermal patch. Primary end point was pain relief; second end points were change in patient quality of life, a degree of satisfaction for patients and clinician, side effects. RESULTS: Between March 2005 and June 2005, 312 patients from 26 participating institutes were registered, but 249 patients completed this study. Total number of patients in each group was 185 in Group A, 64 in Group B. Mean age was 60 years and male to female ratio was 76:24. Severe pain NRS score at 2 weeks after the application of fentanyl was decreased from 7.03 to 4.01, p=0.003. There was a significant improvement in insomnia, social functioning, and quality of life. A degree of satisfaction for patients and clinician was very high. The most common reasons of patients' satisfactions was good pain control. Ninety six patients reported side effect. Nausea was the most common side effect. There was no serious side effect. CONCLUSION: Fentanyl-TTS was effective in both relieving pain with good tolerability and improving the quality of life for patients with radiotherapy induced acute pain and cancer pain treated with radiotherapy. The satisfaction of the patients and doctors was good. There was no major side effect.
Academies and Institutes
;
Acute Pain
;
Analgesics
;
Female
;
Fentanyl*
;
Humans
;
Male
;
Nausea
;
Prospective Studies
;
Quality of Life
;
Radiotherapy*
;
Sleep Initiation and Maintenance Disorders
;
Transdermal Patch*

Result Analysis
Print
Save
E-mail